Skip to content

Intravenous immunoglobuline in the treatment of Rhesus disease of the neonate. A randomized double blind placebo controlled trial.

Intravenous immunoglobuline in the treatment of Rhesus disease of the neonate. A randomized double blind placebo controlled trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON25873
Enrollment
80
Registered
2006-12-07
Start date
2006-08-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhesus disease, fetal, neonatal

Interventions

Study group: prophylactic IvIG as a single dose of 0.75 g/kg within the first 4 hours after birth
Control group: an equal amount of glucose 5% intravenous infusion (placebo).

Sponsors

Leiden University Medical Center (LUMC), Department of Neonatology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Neonates of 35 or more weeks of gestation with Rhesus hemolytic disease admitted to the neonatal nursery of the Leiden University Medical Center (LUMC). Rhesus hemolytic disease was defined as 1. Antibody Dependent Cellular Cytotoxicity-test (ADCC) > 50%, and 2. positive direct Coombs test in a Rh(D) or (c) positive fetus/neonate with a Rh(D) or (c) negative mother respectively and a Rh(D) or (c) positive father respectively. Previous intra-uterine transfusions and the presence of additional antibodies besides anti-D and anti-c are not reasons for exclusion.

Exclusion criteria

Exclusion criteria: 1. Perinatal asphyxia (defined as an Apgar score at 5 minutes less than 3 and/or umbilical cord arterial pH less than 7.0); 2. Neonates with hemolytic disease other than Rh(D) or (c). 3. Neonates with Rh hemolytic disease presenting > 24 hours after birth.

Design outcomes

Primary

MeasureTime frame
1. Use of exchange transfusion (%; proportion of children receiving one or more exchange transfusion); 2. Number of exchange transfusion performed per infant.

Secondary

MeasureTime frame
1. Duration of phototherapy (number of days); 2. Maximum serum bilirubin (mmol/l); 3. Change in bilirubin in first 24 hours (%); 4. Change in bilirubin in first 48 hours (%); 5. Use of top-up red cell transfusion in first week of life (%; proportion of children receiving one or more red cell transfusion and number of transfusions per infant); 6. Use of simple red cell transfusion after first week and until 3 months of life (%; proportion of children receiving one or more red cell transfusion and number of transfusions per infant); 7. Duration of hospital stay (number of days).

Contacts

Public ContactE. Lopriore

Leiden University Medical Center (LUMC), Department of Pediatrics Division of Neonatology, J6-S P.O. Box 9600

e.lopriore@lumc.nl+31 (0)71 5262909

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)